Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Yes, IDEC still has a stake in Rituxan sales. From Genentech's last earnings release: http://www.genentech.com/gene/news/2001/20010412-133216.html

Notice that Genentech paid out $46 million in profit sharing arrangements. IDEC reports on the 19th so from their royalty income we can estimate how much they're bringing in from Rituxan sales.

The profit sharing agreement with IDEC states that royalties are based off of Rituxan's sales performance. Each year, the percentage starts at a lower, but undisclosed, level. As sales increase, IDEC's cut increases to another level, also undisclosed, at which it will remain for the rest of the year. I think the transition to the higher payment usually occurs near the end of Q1.

Charly
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.